Is AOD-9604 Legal in Wisconsin? How to Access It Legally

What AOD-9604 Is and Why Its Legal Status Is Complicated

AOD-9604 is a synthetic fragment of human growth hormone, specifically the 16-amino-acid C-terminal sequence spanning positions 177 to 191 of the hGH peptide chain. Researchers originally hypothesized that this fragment retained hGH's lipolytic (fat-burning) properties while avoiding the insulin-like growth factor 1 (IGF-1) elevation associated with full hGH administration.

The Peptide's Pharmacology in Brief

A 2001 study published in the American Journal of Physiology found that AOD-9604 stimulated lipolysis and inhibited lipogenesis in rodent adipocytes through a mechanism independent of the GH receptor [1]. The peptide does not appear to bind the classic GH receptor pathway that drives IGF-1 production, which is the primary reason clinicians and patients became interested in it as a weight-management adjunct.

Why "Legal" Is the Wrong Single-Word Answer

The legality of AOD-9604 cannot be captured in one word. No federal law schedules it as a controlled substance. The DEA's Controlled Substances Act schedules [2] do not list AOD-9604, meaning possession and prescription are not criminal offenses under federal drug law. The complication arises on the manufacturing and dispensing side: because AOD-9604 is not an FDA-approved finished drug product, any preparation dispensed to a patient must travel through a legally recognized compounding pathway. Skipping that pathway, for example by ordering raw peptide powder from an unregulated overseas supplier, creates serious legal exposure for the prescriber and the patient alike.

The Federal Framework That Actually Governs AOD-9604

Understanding AOD-9604's legal status requires understanding two federal mechanisms: the FDA's bulk drug substances list and the 503A/503B compounding pharmacy framework.

FDA Bulk Drug Substances and the "Category 1 / Category 2" Distinction

The FDA Drug Quality and Security Act of 2013 (DQSA) created a formal process by which stakeholders can nominate bulk drug substances for inclusion on a list that allows compounding pharmacies to use them in preparations [3]. AOD-9604 was nominated for this list. As of 2025, the FDA has not placed AOD-9604 on the final positive list (Category 1, approved for compounding) or the negative list (Category 2, prohibited). It sits in a pending evaluation category.

This distinction matters enormously. The FDA's guidance on 503A compounding states that pharmacies may continue to compound with a nominated bulk substance while it is under evaluation, provided the preparation meets other requirements: a valid patient-specific prescription, no essentially equivalent FDA-approved drug on the market, and a licensed pharmacist preparing it [4]. AOD-9604 has no FDA-approved equivalent, satisfying that criterion.

503A vs. 503B Compounding Pharmacies

Congress created two distinct compounding frameworks under DQSA. Section 503A covers traditional compounding pharmacies that prepare medications for individual patients on a per-prescription basis. Section 503B covers outsourcing facilities that may produce larger batches without individual prescriptions, but must register with the FDA and follow current Good Manufacturing Practice (cGMP) standards [3].

For AOD-9604 in Wisconsin, the practical implication is this: a 503A-registered compounding pharmacy in Wisconsin or another state holding appropriate licensure may prepare AOD-9604 injections or other dosage forms for an individual patient who holds a valid Wisconsin physician's prescription. A 503B outsourcing facility may not compound AOD-9604 in advance without a prescription until the FDA clears it on the positive list.

Wisconsin State Law: What the Wisconsin Pharmacy Examining Board Adds

Wisconsin does not maintain a separate state-level approval list for peptides or bulk compounding substances. The Wisconsin Pharmacy Examining Board, operating under Wisconsin Statutes Chapter 450, licenses pharmacies and pharmacists and incorporates federal standards for compounding by reference [5]. This means Wisconsin pharmacies that compound AOD-9604 must comply with federal 503A/503B rules, USP <797> sterile compounding standards, and Wisconsin's own licensing requirements, but no Wisconsin statute independently prohibits or specifically authorizes AOD-9604.

The Medical Practice Act and Prescriber Authority

Wisconsin's Medical Practice Act (Wisconsin Statutes Chapter 448) grants licensed physicians broad authority to prescribe compounded preparations when a commercially available product does not meet a patient's clinical needs [5]. Because no FDA-approved AOD-9604 product exists, a Wisconsin physician who determines that compounded AOD-9604 is appropriate for a specific patient's weight management or metabolic needs may write a prescription without violating state law.

The prescriber must document medical necessity. Standard practice requires a chart note explaining why the compounded peptide is appropriate and why available FDA-approved therapies (such as semaglutide or tirzepatide for weight management) are inadequate or unsuitable for that specific patient.

Board of Medicine Disciplinary Risk

Wisconsin's Medical Examining Board can discipline physicians for prescribing without a legitimate medical purpose. Prescribing AOD-9604 to a patient without an established patient-physician relationship, a documented clinical evaluation, or any treatment rationale would expose a prescriber to board complaint risk. Ordering it from an unregulated peptide vendor does the same. The legal path is narrow but real: evaluation, prescription, licensed compounding pharmacy, monitored treatment.

Clinical Evidence: What the Research Actually Shows

AOD-9604 has a more substantial clinical trial history than most research peptides, largely because the pharmaceutical company Metabolic Pharmaceuticals pursued FDA approval for it as an obesity drug under the brand name Tyr-hGH frag 177-191 in the early 2000s.

The Phase 2 and Phase 3 Trial Data

A Phase 2 randomized controlled trial (N=300) published findings showing that AOD-9604 at oral doses of 1 mg/day produced statistically significant weight loss compared to placebo over 12 weeks, with a favorable safety profile and no elevation of IGF-1 or fasting glucose [6]. The Phase 3 program, however, did not meet its primary endpoints for clinically meaningful weight loss at the doses tested orally, which contributed to Metabolic Pharmaceuticals withdrawing its FDA application.

This trial history has two important implications. First, it means AOD-9604 has genuine human safety data, which differentiates it from many research peptides sold online with zero clinical trial exposure. Second, it explains why FDA approval was not achieved: the oral formulation's efficacy was insufficient at the doses studied. Clinicians using it today typically prescribe subcutaneous injection formulations, which have different pharmacokinetics than the oral doses studied in those trials.

IGF-1 and Safety Comparisons to Full hGH

Full human growth hormone therapy carries well-documented risks including IGF-1 elevation, insulin resistance, joint swelling, and potential promotion of existing neoplasms [7]. Because AOD-9604 appears to bypass the GH receptor, the IGF-1 signal is not triggered at pharmacologically relevant doses. A 2000 study in Growth Hormone and IGF Research confirmed that AOD-9604 did not significantly raise serum IGF-1 in treated subjects compared to placebo [6]. This profile makes it attractive as a potential adjunct for patients in whom IGF-1 elevation would be contraindicated.

How to Access AOD-9604 Legally in Wisconsin: A Step-by-Step Path

The legal access pathway for a Wisconsin resident involves four discrete steps, each with specific requirements.

Step 1. Clinical Evaluation by a Licensed Wisconsin Provider

The first step is an in-person or telehealth consultation with a Wisconsin-licensed physician, nurse practitioner, or physician assistant who has prescriptive authority. Wisconsin telehealth law (Wisconsin Statute 448.9955) permits providers to establish a patient-physician relationship via synchronous audio-video consultation, meaning patients in rural Wisconsin counties are not required to travel to a specialty clinic [5].

During this consultation, the provider should review:

• Current weight, BMI, and body composition if available
• Prior weight loss therapy history, including any trials of GLP-1 agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound)
• Metabolic labs: fasting glucose, HbA1c, lipid panel, IGF-1 baseline, and thyroid function
• Contraindications including active malignancy, pregnancy, or known hypersensitivity to hGH-derived compounds

Step 2. Prescription Issued with Medical Necessity Documentation

If the provider determines AOD-9604 is appropriate, the prescription must be written for a specific patient (not a standing order or clinic-wide protocol) and transmitted to a licensed compounding pharmacy. The prescription should specify:

• Compound: AOD-9604, typically 300 mcg to 500 mcg per dose
• Route: subcutaneous injection
• Frequency: once daily, typically administered before sleep or before fasted exercise
• Quantity: a defined supply (commonly 30 to 90 days)
• Directions for reconstitution if supplied as lyophilized powder

Step 3. Dispensing by a Licensed 503A Compounding Pharmacy

The pharmacy receiving the prescription must hold an active Wisconsin pharmacy license or, if out-of-state, a non-resident pharmacy permit issued by the Wisconsin Pharmacy Examining Board. The pharmacist must prepare the AOD-9604 preparation according to USP <797> sterile compounding standards, which govern beyond-use dating, sterility testing, and environmental monitoring [4].

Patients should ask their pharmacy for a certificate of analysis (COA) from a third-party analytical laboratory confirming the peptide's identity, purity (>95% by HPLC), and absence of contaminants including bacterial endotoxins. No federal law mandates that compounding pharmacies provide a COA on request, but any reputable 503A pharmacy will supply one.

Step 4. Ongoing Monitoring and Follow-Up

The prescribing provider should schedule follow-up at 4 to 6 weeks to assess response, adverse effects, and any need for dose adjustment. Monitoring labs at 90-day intervals may include fasting IGF-1 (to confirm lack of elevation), fasting glucose, and body composition reassessment if available.

What Is Not Legal: Common Mistakes Wisconsin Residents Make

Several practices that patients encounter online fall outside the legal framework described above.

Purchasing AOD-9604 labeled "for research use only" from a domestic or international peptide vendor and self-injecting it is not legal for human use. The FDA's guidance on research chemicals specifies that a substance intended for human administration must pass through the drug approval or compounding pathway regardless of how the vendor labels it [3]. Vendors using the "research use only" label are specifically doing so to avoid FDA drug manufacturing requirements, not because those requirements do not apply.

Importing AOD-9604 from international sources without a valid prescription and FDA import approval is a separate federal violation under the Federal Food, Drug, and Cosmetic Act. U.S. Customs and Border Protection routinely seizes peptide packages at the border.

Ordering from a telehealth platform that issues a prescription without any clinical evaluation, or that bundles the peptide directly into a paid subscription without a licensed pharmacy in the dispensing chain, likely violates both federal compounding rules and Wisconsin's pharmacy practice act.

AOD-9604 Compared to FDA-Approved Weight-Loss Alternatives in Wisconsin

Wisconsin patients and providers evaluating AOD-9604 should have a clear picture of the FDA-approved field for comparison.

Semaglutide 2.4 mg weekly (Wegovy) produced 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo in STEP-1 (N=1,961, P<0.001) [8]. Tirzepatide 15 mg weekly (Zepbound) produced 20.9% mean body weight loss at 72 weeks in SURMOUNT-1 (N=2,539, P<0.001) [9]. These are FDA-approved, commercially manufactured products with Level 1 evidence supporting their use. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends GLP-1 receptor agonists as first-line pharmacological therapy for adults with BMI >30 or BMI >27 with a weight-related comorbidity [10].

AOD-9604 does not have equivalent efficacy data in its current subcutaneous form, and no head-to-head trial against semaglutide or tirzepatide exists. Providers who prescribe it in Wisconsin are typically doing so in one of three contexts: as an adjunct to GLP-1 therapy, for patients who cannot tolerate GLP-1 agonists due to gastrointestinal side effects, or for patients whose primary goal is fat metabolism improvement rather than scale-weight reduction.

The Endocrine Society notes that "individualized treatment selection based on patient comorbidities, drug tolerability, and treatment goals is appropriate in obesity management" [10], which gives Wisconsin providers legitimate clinical latitude to consider adjunct or alternative approaches when approved therapies are contraindicated or ineffective.

"Compounded peptides occupy a distinct space in obesity medicine: they are not substitutes for approved pharmacotherapy in most patients, but for a defined subset they fill a genuine clinical gap," according to a clinical framework developed by the HealthRX medical team based on review of current compounding law and metabolic trial data.

Practical Costs and Insurance Coverage in Wisconsin

AOD-9604 prepared by a 503A compounding pharmacy in Wisconsin is not covered by any major commercial insurance plan or by Wisconsin Medicaid. The drug has no NDC code (National Drug Code) because it is not an FDA-approved finished product, making insurance billing structurally impossible under standard pharmacy benefit management systems.

Out-of-pocket costs for a 30-day supply of compounded AOD-9604 (subcutaneous injection, 300 to 500 mcg/day) range from approximately $80 to $200 depending on the pharmacy and formulation. The consultation fee and follow-up monitoring costs are additional. Patients using health savings accounts (HSAs) or flexible spending accounts (FSAs) may be able to use those funds if their provider issues documentation of medical necessity, though FSA/HSA administrators vary in how they classify compounded peptides.